<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00258466</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000447161</org_study_id>
    <secondary_id>P30CA022453</secondary_id>
    <secondary_id>WSU-D-2879</secondary_id>
    <secondary_id>WSU-HIC-047405MP4F</secondary_id>
    <nct_id>NCT00258466</nct_id>
  </id_info>
  <brief_title>Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Prostate Cancer</brief_title>
  <official_title>Phase III Trial of Neutron + Photon Radiation Versus Photon + Hypofractionated Intensity Modulated Radiation Therapy in Localized Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Ann Karmanos Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Barbara Ann Karmanos Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays and other types of radiation to kill&#xD;
      tumor cells. Giving radiation therapy in different ways may kill more tumor cells. It is not&#xD;
      yet known which type of radiation therapy is more effective in treating prostate cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying different types of radiation therapy to&#xD;
      compare how well they work in treating patients with stage I, stage II, or stage III prostate&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the efficacy of neutron and photon radiotherapy vs hypofractionated intensity&#xD;
           modulated radiation, in terms of a lower frequency of chronic complication rate (chronic&#xD;
           toxicity and disease-free survival), in patients with favorable to intermediate&#xD;
           prognosis, stage I-III adenocarcinoma of the prostate.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to stage&#xD;
      of disease (T1 vs T2 vs T3). Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients undergo neutron radiotherapy over 15-45 minutes 5 days a week for 2&#xD;
           weeks followed by photon radiotherapy over 15-45 minutes 5 days a week for 5 weeks.&#xD;
&#xD;
        -  Arm II: Patients undergo photon radiotherapy over 15-45 minutes 5 days a week for 5&#xD;
           weeks followed by hypofractionated photon irradiation over 15-45 minutes 5 days a week&#xD;
           for 2 weeks.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically for 5 years and then&#xD;
      yearly thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 300 patients (150 per treatment arm) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of chronic grade 2 or higher toxicity as measured by RTOG/EORTC late morbidity scoring scheme at 1, 4, 8, and 12 months after treatment, then every 6 months for 5 years, then annually</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease free survival at 1, 4, 8, and 12 months after treatment, then every 6 months for 5 years, then annually</measure>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the prostate&#xD;
&#xD;
               -  Stage I-III disease (T1-T3, N0, M0)&#xD;
&#xD;
               -  No clinical or radiographic evidence of metastasis&#xD;
&#xD;
                    -  If prostate-specific antigen (PSA) ≥ 10.0 ng/mL and Gleason score is 7, a&#xD;
                       radioisotope bone scan must show no evidence of metastasis&#xD;
&#xD;
                    -  No evidence of lymphatic or visceral metastases of the abdomen or pelvis on&#xD;
                       CT scan or MRI&#xD;
&#xD;
          -  PSA ≤ 20 ng/mL&#xD;
&#xD;
          -  Gleason score ≤ 7 (if stage T3 , score must be &lt; 7)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 10 years&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other malignancy within the past 5 years except basal cell or squamous cell skin&#xD;
             cancer&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Prior hormonal therapy allowed provided it was initiated no more than 2 months ago,&#xD;
             and may include the following:&#xD;
&#xD;
               -  Luteinizing hormone-releasing hormone agonists (e.g., goserelin, leuprolide)&#xD;
&#xD;
               -  Anti-androgens (e.g., flutamide, bicalutamide)&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior pelvic irradiation&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  No prior radical prostatectomy&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey D. Forman, MD, FACR</last_name>
    <role>Study Chair</role>
    <affiliation>Weisberg Cancer Treatment Center</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>November 23, 2005</study_first_submitted>
  <study_first_submitted_qc>November 23, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2005</study_first_posted>
  <last_update_submitted>April 5, 2013</last_update_submitted>
  <last_update_submitted_qc>April 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>stage I prostate cancer</keyword>
  <keyword>stage II prostate cancer</keyword>
  <keyword>stage III prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

